Umbilical cord blood transplantation supplemented with the infusion of mesenchymal stem cell for an adolescent patient with severe aplastic anemia: a case report and review of&amp;nbsp;literature

Luan, Chengxin; Chen, Runzhe; Chen, Baoan; Ding, Jia-Hua; Ni, Ming

doi:10.2147/ppa.s81509

Cited by 4 publications

(5 citation statements)

References 58 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…UCBT has many advantages for treating WAS, as compared to other types of HSCT. For example, the acquisition of CB is easy, collection of CB is harmless, and the CB handling process, such as thawing, does not induce loss of cell proliferation[4,13-16]. In addition, CB transplantation showed a lower risk of acute and chronic GVHD than other transplantation strategies using a different cell source[17,18].…”

Section: Discussionmentioning

confidence: 99%

“…The advantage of UCBT is that one can search and prepare umbilical cord blood on time without delay, and it has a low incidence and severity of graft versus host disease (GVHD)[3]. However, slow hematopoietic reconstruction and increasing probability of engraftment failure prevent widespread use of UCBT[4]. As a result, the patients who experience slow immune reconstitution are at high risk of infection.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Child with Wiskott–Aldrich syndrome underwent atypical immune reconstruction after umbilical cord blood transplantation: a case report

Li¹,

Hu²

2019

WJCC

View full text Add to dashboard Cite

BACKGROUNDTimely reconstitution of a donor-derived immune system is important for recovery and long-term survival of patients after allogeneic hematopoietic stem cell transplantation (HSCT). We describe a case of Wiskott–Aldrich syndrome (WAS) treated by umbilical cord blood transplantation (UCBT) with atypical immune reconstruction.CASE SUMMARYA 1-year-old Chinese male infant was diagnosed with WAS. WAS gene sequencing identified the mutation c.777 + 1G>A (IVS8). On August 8, 2017, he was admitted to our hospital for HSCT. We selected an unrelated Human leukocyte antigen 6/10-matched donor for UCBT. After HSCT, the immune reconstitution process was atypical, the lymphocytes reached 0.5 × 109/L on day 23, and the neutrophils reached 0.5 × 109/L on day 34. The patient’s recovery throughout the year was good.CONCLUSIONAn increase in lymphocytes (especially T cells) earlier than granulocytes may be a marker of a good prognosis in UCBT.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Child with Wiskott–Aldrich syndrome underwent atypical immune reconstruction after umbilical cord blood transplantation: a case report

Li¹,

Hu²

2019

WJCC

View full text Add to dashboard Cite

show abstract

“…In the collective pool of patients that go to HCT, AA patients are at high risk of graft failure. There is evidence that supporting patients with HSCs in addition to MSCs will better support hematopoiesis and engraftment[ 59 - 61 ]. Initial case reports adding MSCs to transplantation were promising.…”

Section: Mscs For Immunomodulatory and Regenerative Therapymentioning

confidence: 99%

“…Initial case reports adding MSCs to transplantation were promising. Luan et al[ 61 ] reported a case of a patient with severe AA that underwent matched sibling cord blood transplant but had delayed engraftment; after giving a cord-blood-derived MSC infusion, the patient began to engraft and pancytopenia improved. Similarly, a report on 2 patients with severe AA who had graft failure after HCT were given second transplant from the same donor with addition of MSCs from a haploidentical maternal donor and they were able to engraft[ 59 ].…”

Section: Mscs For Immunomodulatory and Regenerative Therapymentioning

confidence: 99%

Yin and Yang of mesenchymal stem cells and aplastic anemia

Broglie

Margolis

Medin

2017

WJSC

View full text Add to dashboard Cite

Acquired aplastic anemia (AA) is a bone marrow failure syndrome characterized by peripheral cytopenias and bone marrow hypoplasia. It is ultimately fatal without treatment, most commonly from infection or hemorrhage. Current treatments focus on suppressing immune-mediated destruction of bone marrow stem cells or replacing hematopoietic stem cells (HSCs) by transplantation. Our incomplete understanding of the pathogenesis of AA has limited development of targeted treatment options. Mesenchymal stem cells (MSCs) play a vital role in HSC proliferation; they also modulate immune responses and maintain an environment supportive of hematopoiesis. Some of the observed clinical manifestations of AA can be explained by mesenchymal dysfunction. MSC infusions have been shown to be safe and may offer new approaches for the treatment of this disorder. Indeed, infusions of MSCs may help suppress auto-reactive, T-cell mediated HSC destruction and help restore an environment that supports hematopoiesis. Small pilot studies using MSCs as monotherapy or as adjuncts to HSC transplantation have been attempted as treatments for AA. Here we review the current understanding of the pathogenesis of AA and the function of MSCs, and suggest that MSCs should be a target for further research and clinical trials in this disorder.

show abstract

“…The patient experienced delayed hematopoietic recovery after transplantation, but hematopoietic function improved after the infusion of UC-MSCs. This suggests that early infusion of MSCs after HCT can promote the recovery of hematopoietic function [ 32 ]. Wu et al .…”

Section: Introductionmentioning

confidence: 99%

A review of the application of mesenchymal stem cells in the field of hematopoietic stem cell transplantation

2023

View full text Add to dashboard Cite

Hematopoietic stem cell transplantation (HSCT) is an effective treatment for many malignant hematological diseases. Mesenchymal stem cells (MSCs) are nonhematopoietic stem cells with strong self-renewal ability and multidirectional differentiation potential. They have the characteristics of hematopoietic support, immune regulation, tissue repair and regeneration, and homing. Recent studies have shown that HSCT combined with MSC infusion can promote the implantation of hematopoietic stem cells and enhance the reconstruction of hematopoietic function. Researchers have also found that MSCs have good preventive and therapeutic effects on acute and chronic graft-versus-host disease (GVHD), but there is still a lack of validation in large-sample randomized controlled trials. When using MSCs clinically, it is necessary to consider their dose, source, application time, application frequency and other relevant factors, but the specific impact of the above factors on the efficacy of MSCs still needs further clinical trial research. This review introduces the clinical roles of MSCs and summarizes the most recent progress concerning the use of MSCs in the field of HSCT, providing references for the later application of the combination of MSCs and HSCT in hematological diseases.

show abstract

Umbilical cord blood transplantation supplemented with the infusion of mesenchymal stem cell for an adolescent patient with severe aplastic anemia: a case report and review of literature

Cited by 4 publications

References 58 publications

Child with Wiskott–Aldrich syndrome underwent atypical immune reconstruction after umbilical cord blood transplantation: a case report

Child with Wiskott–Aldrich syndrome underwent atypical immune reconstruction after umbilical cord blood transplantation: a case report

Yin and Yang of mesenchymal stem cells and aplastic anemia

A review of the application of mesenchymal stem cells in the field of hematopoietic stem cell transplantation

Contact Info

Product

Resources

About